Home/Pipeline/Antibody Platform Enhancement

Antibody Platform Enhancement

Broad (Platform for mAb production)

Development/Scale-upActive

Key Facts

Indication
Broad (Platform for mAb production)
Phase
Development/Scale-up
Status
Active
Company

About Prolific Machines

Prolific Machines is pioneering an optogenetic biomanufacturing platform that uses light to dynamically control cellular processes, decoupling cell growth from protein production to boost titers and improve product quality. Their technology addresses key bottlenecks in producing complex biologics like antibodies, biosimilars, and multispecifics, with demonstrated titer increases of up to 5.6-fold. The company, which is advancing through the FDA's Emerging Technology Program, offers a combination of proprietary cell lines, illumination hardware, and AI-driven bioprocess optimization as a flexible solution for therapeutic developers. By creating a new infrastructure layer for biology, Prolific aims to enable next-generation therapeutics across cell therapy and synthetic biology.

View full company profile